18f-mk6240
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 5, 2018 (NCT03389100)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06999434 | Phase 1 | May 5, 2025 | National Institute on Aging (NIA), National Institutes of Health (NIH), Yale University |
| NCT05464368 | Phase 1 | Aug 31, 2022 | Roche, Washington University in St. Louis |
| NCT03389100 | Phase 2 | Mar 5, 2018 | Columbia University, Hebrew Home at Riverdale, National Institute on Aging (NIA) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Aging (NIA) | Government | 2 | 0 | 2 | 2018 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Hebrew Home at Riverdale | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
| Roche | For profit | 1 | 0 | 1 | 2022 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2025 |
7 organizations
Page 1 / 1